Home›Trial›NCT05697861
NCT05697861RECRUITING

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Study Summary

This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Conditions
Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyTransthyretin-Related (ATTR) Familial Amyloid CardiomyopathyWild-Type Transthyretin Cardiac Amyloidosis
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
NTLA
Intellia Therapeutics
Gene Editing
C55/100
Study Details
Enrollment72 participants
Primary Completion—
Lead SponsorIntellia Therapeutics
Data Retrieved2026-04-11 04:23:01.073864+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 72 participants
Sponsor Catalyst Profile

Intellia Therapeutics (NTLA) is the sponsoring company for this trial. BiotechSign currently grades this company C (55/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NTLA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.